Literature DB >> 22237833

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

Andrew Siderowf1, Danna Jennings, Shirley Eberly, David Oakes, Keith A Hawkins, Albert Ascherio, Matthew B Stern, Kenneth Marek.   

Abstract

To test the association between impaired olfaction and other prodromal features of PD in the Parkinson At-Risk Syndrome Study. The onset of olfactory dysfunction in PD typically precedes motor features, suggesting that olfactory testing could be used as a screening test. A combined strategy that uses other prodromal nonmotor features, along with olfactory testing, may be more efficient than hyposmia alone for detecting the risk of PD. Individuals with no neurological diagnosis completed a mail survey, including the 40-item University of Pennsylvania Smell Identification Test, and questions on prodromal features of PD. The frequency of reported nonmotor features was compared across individuals with and without hyposmia. A total of 4,999 subjects completed and returned the survey and smell test. Of these, 669 were at or below the 15th percentile based on age and gender, indicating hyposmia. Hyposmics were significantly more likely to endorse nonmotor features, including anxiety and depression, constipation, and rapid eye movement sleep behavior disorder symptoms, and to report changes in motor function. Twenty-six percent of subjects with combinations of four or more nonmotor features were hyposmic, compared to 12% for those reporting three or fewer nonmotor features (P < 0.0001). Hyposmia is associated with other nonmotor features of PD in undiagnosed individuals. Further assessment of hyposmic subjects using more specific markers for degeneration, such as dopamine transporter imaging, will evaluate whether combining hyposmia and other nonmotor features is useful in assessing the risk of future neurodegeneration.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22237833      PMCID: PMC6342466          DOI: 10.1002/mds.24892

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  76 in total

1.  Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Authors:  Lama M Chahine; Daniel Weintraub; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

Review 2.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

3.  Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.

Authors:  Hua Wang; Anzari Atik; Tessandra Stewart; Carmen Ginghina; Patrick Aro; Kathleen F Kerr; John Seibyl; Danna Jennings; Poul Henning Jensen; Kenneth Marek; Min Shi; Jing Zhang
Journal:  Neurobiol Dis       Date:  2018-04-27       Impact factor: 5.996

Review 4.  Precision medicine for disease modification in Parkinson disease.

Authors:  Alberto J Espay; Patrik Brundin; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

5.  Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Authors:  Danna Jennings; Andrew Siderowf; Matthew Stern; John Seibyl; Shirley Eberly; David Oakes; Kenneth Marek
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

Review 6.  An update on the diagnosis and treatment of Parkinson disease.

Authors:  Philippe Rizek; Niraj Kumar; Mandar S Jog
Journal:  CMAJ       Date:  2016-05-24       Impact factor: 8.262

Review 7.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

8.  Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Authors:  Michelle E Fullard; Sharon X Xie; Ken Marek; Matthew Stern; Danna Jennings; Andrew Siderowf; Allison W Willis; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2017-09-14       Impact factor: 10.338

Review 9.  Is there a need to redefine Parkinson's disease?

Authors:  Philipp Mahlknecht; Werner Poewe
Journal:  J Neural Transm (Vienna)       Date:  2013-05-29       Impact factor: 3.575

10.  Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Authors:  Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.